0001140361-21-041286.txt : 20211210 0001140361-21-041286.hdr.sgml : 20211210 20211210210052 ACCESSION NUMBER: 0001140361-21-041286 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211208 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cherington Charles CENTRAL INDEX KEY: 0001448698 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11460 FILM NUMBER: 211486778 MAIL ADDRESS: STREET 1: ONE BOW STREET CITY: CAMBRIDGE STATE: MA ZIP: 02138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Brooklyn ImmunoTherapeutics, Inc. CENTRAL INDEX KEY: 0000748592 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 311103425 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 140 58TH STREET, BUILDING A STREET 2: SUITE 2100 CITY: BROOKLYN STATE: NY ZIP: 11220 BUSINESS PHONE: (212) 582-1199 MAIL ADDRESS: STREET 1: 140 58TH STREET, BUILDING A STREET 2: SUITE 2100 CITY: BROOKLYN STATE: NY ZIP: 11220 FORMER COMPANY: FORMER CONFORMED NAME: NTN BUZZTIME INC DATE OF NAME CHANGE: 20051230 FORMER COMPANY: FORMER CONFORMED NAME: NTN COMMUNICATIONS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ALROY INDUSTRIES INC DATE OF NAME CHANGE: 19850411 4 1 form4.xml FORM 4 X0306 4 2021-12-08 0000748592 Brooklyn ImmunoTherapeutics, Inc. BTX 0001448698 Cherington Charles C/O BROOKLYN IMMUNOTHERAPEUTICS, INC. 140 58TH STREET, BUILDING A, SUITE 2100 BROOKLYN NY 11220 true Common Stock 2021-06-01 5 J 0 92 0 A 5894193 D Stock Option 5.94 2021-12-08 4 A 0 67000 0 A 2031-12-07 Common Stock 67000 67000 D Represents a stock dividend declared on shares of the Issuer's Series A Preferred Stock. A total of 22,336 of the shares subject to the option vest and become exercisable as of 12:01 a.m. Eastern time on the date of the issuer's 2022 Annual Meeting of Stockholders and the remaining 44,664 shares vest and become exercisable in equal monthly installments over the following 24 months, subject to continued service through each vesting date. /s/ Mark L. Johnson, Attorney-in-Fact for Charles Cherington 2021-12-10